Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: Effectiveness of a two-in-one inhaler versus separate inhalers

American Journal of Managed Care

Volumn 8, Issue 10, 2002, Pages 902-911

  Chrischilles, Elizabeth ^a   Gilden, Daniel ^a   Kubisiak, Joanna ^a   Rubenstein, Linda ^a   Shah, Hemal ^a  

^a Department of Epidemiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LEUKOTRIENE RECEPTOR AFFECTING AGENT; METHYLXANTHINE DERIVATIVE; NEDOCROMIL; SALBUTAMOL; SALMETEROL; STEROID;

ADULT; AEROSOL; AGE; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; DISEASE SEVERITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; EMERGENCY WARD; FEMALE; FOLLOW UP; GENDER; HEALTH CARE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INHALER; INTERMETHOD COMPARISON; LOWER RESPIRATORY TRACT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, INHALATION; ADULT; AGED; ALBUTEROL; BRONCHODILATOR AGENTS; COHORT STUDIES; DRUG THERAPY, COMBINATION; EMERGENCY SERVICE, HOSPITAL; FEMALE; GUIDELINE ADHERENCE; HOSPITALIZATION; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 0036798629     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bone R, Boyars M, Braun SR, et al, for the Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest. 1994;105:1411-1419.
2. Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ Jr. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with chronic obstructive pulmonary disease. Chest. 1999;115:966-971.
3. Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone in COPD. Chest. 1999;115:635-641.
4. Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of COPD. Dey Combination Solution Study Group. Respiration. 1998;65(5):354-362.
5. Tashkin DP. Multiple dose regimens: Impact on compliance. Chest. 1995;107:176S-182S.
6. Osborne ML, Vollmer WM, Buist AS. Periodicity of asthma, emphysema, and chronic bronchitis in a northwest health maintenance organization. Chest. 1996;110:1458-1462.
7. Kraut A, Wald R, Mustard C. Prevalence of physician-diagnosed asthma by occupational groupings in Manitoba, Canada. Am J Ind Med. 1997;32:275-282.
8. Tager IB, Segal MR. Temporal trends in chronic obstructive lung disease case fatality in hospitalized US veterans: 1970-1987. Chest. 1991;99:1126-1133.
9. Vilkman Sirrku, Keistinen T, Tuuponen T, Kivela S. Age distribution of patients treated in hospital for chronic obstructive pulmonary disease. Age Aging. 1996;25:109-112.
10. Vestbo J, Prescott E, Lange P, Schnohr P, Jensen G. Vital prognosis after hospitalization for COPD: A study of a random population sample. Respir Med. 1998;92:772-776.
11. Cooreman J, Thom TJ, Higgins MW. Mortality from chronic obstructive pulmonary diseases and asthma in France, 1969-1983: Comparisons with the United States and Canada. Chest. 1990;97:213-219.
12. Meijers JM, Swaen GMH, Slangen JJM. Mortality of Dutch coal miners in relation to pneumoconiosis, chronic obstructive pulmonary disease, and lung function. Occup Environ Med. 1997;54:708-713.
13. Rawson NSB, Malcolm E. Validity of the recording of ischaemic heart disease and chronic obstructive pulmonary disease in the Saskatchewan Healthcare data files. Stat Med. 1995;14:2627-2643.
14. Anderson HR, Spix C, Medina S, et al. Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: Results from the APHEA project. Eur Respir J. 1997;10:1064-1071.
15. Wever-Hess J, Wever AMJ, Yntema JL. Mortality and morbidity from respiratory diseases in childhood in the Netherlands, 1980-7. Eur Respir J. 1991;4:429-433.
16. Cydulka RK, McFadden ER, Emerman CL, Sivinski LD, Pisanelli W, Rimm AA. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. Am J Respir Care Med. 1997;156:1807-1812.
17. Wever-Hess J, Wever AMJ. Asthma statistics in the Netherlands 1980-94. Respir Med. 1997;91:417-422.
18. Spitzer WO, Suissa S, Ernst P, et al. The use of b-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326:501-506.
19. Van Ganse E, Hubloue I, Vincken W, et al. Actual use of inhaled corticosteroids and risk of hospitalisation: A case-control study. Eur J Clin Pharmacol. 1997;51:449-454.